Reports
Sale
Europe Tumor Ablation Market Size, Share, Trends, Growth: By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Ablation Technologies; By Application: Kidney Cancer, Liver Cancer, Others; By Mode of Treatment; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Europe Tumor Ablation Market Outlook
The Europe tumor ablation market size was valued at USD 0.3 billion in 2023, driven by the rising preference for minimally invasive treatment procedures in the region. The market is expected to grow at a CAGR of 12.92% during the forecast period of 2024-2032, with the values likely to rise from USD 0.4 billion in 2024 to USD 0.9 billion by 2032.
Key Takeaways
- In December 2023, Clinical Laserthermia Systems (CLS) participated in IRMPROFT (a research study) with its TRANBERG system, a cutting-edge solution for minimally invasive, image-guided focal laser ablation aimed at treating cancer. The application of tumor ablation with combination therapies is projected to increase the Europe tumor ablation market growth in the forecast period.
- The market is affected by the rising number of FDA approvals for new tumor ablation systems, including Medtronic receiving a 510(k) clearance for OsteoCool™ 2.0, their new tumor ablation system.
- Cancer is the fourth most common cause of death in Europe, causing the tumor ablation market to keep expanding with innovations and technological advancements.
Europe Tumor Ablation Market Analysis
Tumor ablation is a minimally invasive procedure that uses extreme heat or cold to shrink or destroy tumors. It involves inserting a needle-tipped catheter into the tumor with the help of imaging guidance. The technological advancements along with the innovation of new procedures are expected to generate profitable opportunities, thereby, contributing to increased Europe tumor ablation market share.
The rising geriatric population and growing prevalence of cancer cases are amongst some of the most influential factors responsible for driving the growth of the market. After cardiovascular diseases, cancer is the most common cause of death and morbidity in Europe accounting for more than 3.7 million new cases and 1.9 million deaths each year in Europe. The market is also experiencing significant traction due to the rising demand for minimally invasive treatments and increasing awareness about ablation procedures, propelling the heightening of the Europe tumor ablation market demand.
In March 2024, Medtronic plc received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OsteoCool™ 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. Integrated with several new features OsteoCool is poised to bring innovation to the market. Portfolio expansions by market players are expected to influence the Europe tumor ablation market size in the coming years.
The market is further influenced by the increasing number of research activities, and efforts of key players towards expanding their global footprint as well as enhance the existing technologies present in the market. In December 2023, Clinical Laserthermia Systems (CLS) announced participation in a new research study, called IRMPROFT, to examine the use of MRI in combination with biopsies to diagnose residual prostate cancer post-focal therapy. The company is participating in this study with their TRANBERG system, a cutting-edge solution for minimally invasive, image-guided focal laser ablation aimed at treating cancer. The application of tumor ablation in combination with other therapies is poised to drive market growth in the forecast period.
Europe Tumor Ablation Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| By Technology | Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, and other ablation technologies. |
| By Application | Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Bone Cancer |
| By Mode of Treatment | Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation |
| By End User | Hospitals, Cancer Specialty Clinics, others |
| By Country | United Kingdom, Germany, France, Italy |
Europe Tumor Ablation Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- EDAP TMS
- Mermaid Medical
- BVM Medical Limited
- Cortex Technology
- Olympus Corporation
- BIOTRONIK SE & Co KG
- Boston Scientific Corporation
- Medtronic plc
- AngioDynamics, Inc.
- Merit Medical Systems, Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Application |
|
| Breakup by Mode of Treatment |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Tumor Ablation Market Overview
3.1 Europe Tumor Ablation Market Historical Value (2017-2023)
3.2 Europe Tumor Ablation Market Forecast Value (2024-2032)
4 Europe Tumor Ablation Market Landscape*
4.1 Europe Tumor Ablation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Tumor Ablation: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Application
5 Europe Tumor Ablation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Tumor Ablation Market Segmentation (2017-2032)
6.1 Europe Tumor Ablation Market (2017-2032) by Technology
6.1.1 Market Overview
6.1.2 Radiofrequency Ablation
6.1.3 Microwave Ablation
6.1.4 Cryoablation
6.1.5 Irreversible Electroporation Ablation
6.1.6 Other Ablation Technologies
6.2 Europe Tumor Ablation Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Kidney Cancer
6.2.3 Liver Cancer
6.2.4 Breast Cancer
6.2.5 Lung Cancer
6.2.6 Prostate Cancer
6.2.7 Bone Cancer
6.3 Europe Tumor Ablation Market (2017-2032) by Mode of Treatment
6.3.1 Market Overview
6.3.2 Surgical Ablation
6.3.3 Laparoscopic Ablation
6.3.4 Percutaneous Ablation
6.4 Europe Tumor Ablation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Cancer Specialty Clinics
6.4.4 Others
6.5 Europe Tumor Ablation Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 United Kingdom
6.5.3 Germany
6.5.4 France
6.5.5 Italy
7 United Kingdom Tumor Ablation Market (2017-2032)
7.1 United Kingdom Tumor Ablation Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Radiofrequency Ablation
7.1.3 Microwave Ablation
7.1.4 Cryoablation
7.1.5 Irreversible Electroporation Ablation
7.1.6 Other Ablation Technologies
7.2 United Kingdom Tumor Ablation Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Kidney Cancer
7.2.3 Liver Cancer
7.2.4 Breast Cancer
7.2.5 Lung Cancer
7.2.6 Prostate Cancer
7.2.7 Bone Cancer
7.3 United Kingdom Tumor Ablation Market (2017-2032) by Mode of Treatment
7.3.1 Market Overview
7.3.2 Surgical Ablation
7.3.3 Laparoscopic Ablation
7.3.4 Percutaneous Ablation
7.4 United Kingdom Tumor Ablation Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals
7.4.3 Cancer Specialty Clinics
7.4.4 Others
8 Germany Tumor Ablation Market (2017-2032)
8.1 Germany Tumor Ablation Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Radiofrequency Ablation
8.1.3 Microwave Ablation
8.1.4 Cryoablation
8.1.5 Irreversible Electroporation Ablation
8.1.6 Other Ablation Technologies
8.2 Germany Tumor Ablation Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Kidney Cancer
8.2.3 Liver Cancer
8.2.4 Breast Cancer
8.2.5 Lung Cancer
8.2.6 Prostate Cancer
8.2.7 Bone Cancer
8.3 Germany Tumor Ablation Market (2017-2032) by Mode of Treatment
8.3.1 Market Overview
8.3.2 Surgical Ablation
8.3.3 Laparoscopic Ablation
8.3.4 Percutaneous Ablation
8.4 Germany Tumor Ablation Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals
8.4.3 Cancer Specialty Clinics
8.4.4 Others
9 France Tumor Ablation Market (2017-2032)
9.1 France Tumor Ablation Market (2017-2032) by Technology
9.1.1 Market Overview
9.1.2 Radiofrequency Ablation
9.1.3 Microwave Ablation
9.1.4 Cryoablation
9.1.5 IrrevAblationersible Electroporation Ablation
9.1.6 Other Technologies
9.2 France Tumor Ablation Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Kidney Cancer
9.2.3 Liver Cancer
9.2.4 Breast Cancer
9.2.5 Lung Cancer
9.2.6 Prostate Cancer
9.2.7 Bone Cancer
9.3 France Tumor Ablation Market (2017-2032) by Mode of Treatment
9.3.1 Market Overview
9.3.2 Surgical Ablation
9.3.3 Laparoscopic Ablation
9.3.4 Percutaneous Ablation
9.4 France Tumor Ablation Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals
9.4.3 Cancer Specialty Clinics
9.4.4 Others
10 Italy Tumor Ablation Market (2017-2032)
10.1 Italy Tumor Ablation Market (2017-2032) by Technology
10.1.1 Market Overview
10.1.2 Radiofrequency Ablation
10.1.3 Microwave Ablation
10.1.4 Cryoablation
10.1.5 Irreversible Electroporation Ablation
10.1.6 Other Ablation Technologies
10.2 Italy Tumor Ablation Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Kidney Cancer
10.2.3 Liver Cancer
10.2.4 Breast Cancer
10.2.5 Lung Cancer
10.2.6 Prostate Cancer
10.2.7 Bone Cancer
10.3 Italy Tumor Ablation Market (2017-2032) by Mode of Treatment
10.3.1 Market Overview
10.3.2 Surgical Ablation
10.3.3 Laparoscopic Ablation
10.3.4 Percutaneous Ablation
10.4 Italy Tumor Ablation Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Cancer Specialty Clinics
10.4.4 Others
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 EDAP TMS
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Mermaid Medical
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 BVM Medical Limited
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Cortex Technology
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Olympus Corporation
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 BIOTRONIK SE & Co KG
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Boston Scientific Corporation
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Medtronic plc
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 AngioDynamics, Inc.
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Merit Medical Systems, Inc.
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Europe Tumor Ablation Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 0.3 billion in 2023 driven by the rising geriatric population in the region.
The market is anticipated to grow at a CAGR of 12.92% during the forecast period of 2024-2032, likely to reach a market value of USD 0.9 billion by 2032.
Factors contributing to the market demand include the rising geriatric population and the prevalence of cancer in the region.
One of the significant trends in the market is the increasing technological advancement in the ablation processes like microwave ablation, and cryoablation among others.
By technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other ablation technologies.
It finds wide applications in kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and bone cancer.
By treatment, the market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation.
End users of the market are hospitals, cancer specialty clinics, and others.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.
The key players in the market are EDAP TMS, Mermaid Medical, BVM Medical Limited, Cortex Technology, Olympus Corporation, BIOTRONIK SE & Co KG, Boston Scientific Corporation, AngioDynamics, Inc., Merit Medical Systems, Inc., and Medtronic plc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER